

2023-2027 Asia-Pacific Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-An 18-Country Analysis-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/221B1A996F56EN.html

Date: September 2023

Pages: 0

Price: US\$ 11,600.00 (Single User License)

ID: 221B1A996F56EN

Abstracts

The report is available in Local PDF, Global PDF, and Data Pack formats (supplier shares, test volumes, sales forecasts). The report is delivered in both Excel and PDF. This new 18-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test. The report is available by section, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale



The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

Oncogenes %li%Biochemical
Markers %li%Growth Factors
%li%Colony Stimulating Factors
%li%Hormones
%li%Immunohistochemical Stains
%li%Lymphokines

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen



Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.

Five-year test volume and sales forecasts for major cancer diagnostic assays.

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies.

Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new



products in R&D.

The companies analyzed in the report include:

Abbott, Affymetrix, Beckman Coulter/Danaher/Cepheid, Becton Dickinson, bioMerieux, Bio-Rad, DiaSorin, Eiken Chemical, Elitech Group, Enzo Biochem, Fujifilm Wako, Fujirebio, Grifols, Hologic, Leica Biosystems, Perkin Elmer, Qiagen, QuidelOrtho, Roche, Siemens Healthineers, Takara Bio, Thermo Fisher and others.Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
- 1. Breast Cancer



- 2. Lung Cancer
- 3. Colon and Rectum Cancer
- 4. Prostate Cancer
- 5. Stomach Cancer
- 6. Leukemia
- 7. Lymphoma
- 8. Oral Cancer
- 9. Skin Cancer
- 10. Uterine Cancer
- 11. Ovarian Cancer
- 12. Bladder Cancer
- B. Major Current and Emerging Cancer Diagnostic Tests
- 1. Introduction
- 2. Tumor Marker Classification
- 3. ACTH
- 4. Alpha-Fetoprotein (AFP)
- 5. Beta-2 Microglobulin
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. Calcitonin
- 10. Carcinoembrionic Antigen (CEA)
- 11. Estrogen and Progesterone Receptors
- 12. Ferritin
- 13. Gastrin
- 14. Human Chorionic Gonadotropin (HCG)
- 15. Insulin
- 16. NSE
- 17. Occult Blood
- 18. PAP Smear/HPV
- 19. Prostatic Acid Phosphatase (PAP)
- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
- 27. Oncogenes



 : :Abl/abl-bcr

 : :AIB1

 : :BCL-2

 : :BRCA1

 : :CD44

 : :C-fos

 : :C-myb

 : :C-myc

 : :CYP-17

 : :Erb-B

 : :HPC1

 : :N-myc

 : :P40

 : :P51

 : :P53

 : :PIK3CA

 : :PTI-1

 : :Ras

 : :Reg

 : :Sis

 : :Src and others

28. Polypeptide Growth Factors

 : :Basic Fibroblast Growth Factor

 : :Beta-TGF

 : :Cachectin (TNT)

 : :Calmodulin

 : :ECFR

 : :Nerve Growth Factor (NGF)

 : :Epidermal Growth Factor (EGF)

 : :Ornithine Decarboxylase

 : :Transferrin

 : :Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

 : :Alpha-Interferon

 : :B Cell Growth Factors

 : :B Cell Growth Factor (BCGF)

 : :Gamma-Interferon



 : :Interleukin-1 (IL-1)

 : :Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

 : :N-Acetylglucosamine

 : :Actin

 : :Alpha-Actin

 : :Antineuronal Antibodies

 : :7B2

 : :B72.3

 : :Bax

 : :BCD-F9

 : :BLCA-4

 : :Blood Group Antigens A,B,H

 : :CA

 : :CA 72-4/TAG-72

 : :CA

 : :CA-242

 : :CA-549

 : :CAM

 : :CAR-3

 : :Cathepsin-D

 : :Chromogranin A and B

 : :Cluster 1 Antigen

 : :Cluster-5/5A Antigen

 : :CTA

 : :CU18

 : :DR-70

 : :DU-PAN-2

 : :Endometrial Bleeding Associated Factor

 : :Endostatin

 : :Epithelial Membrane Antigen

 : :Feulgen Hydrolysis

 : :Fibronectin

 : :FSH

 : :(1-\$\$\$\$3)-L-fucosyltransferase

 : :Gastrin-Releasing Peptide (GRP)

 : :GDCFP-15

 : :Glucagon



 : :Glycoamines

 : :H23 : :Her-2

 : :Human Carcinoma Antigen

 : :HPA : :HSP27

 : :Intermediate Filaments

 : :Cytokeratins/CK18/Cyfra 21-1

 : :Desmin

 : :Gliofibrillary Acid Protein

 : :Neurofilaments

 : :Vimentin

 : :KA

 : :Kinases : :KP16D3

 : :LAI

 : :Leukocyte Common Antigen

 : :Lewis Antigens

 : :Lysophosphatidic Acid (LPA)

 : :Ma 695/Ma : :MABDF3

 : :MAG : :ME1

 : :Minactivin : :MN/CA9

 : :MSA

 : :Mucin Cancer Antigen (MCA) : :Multiple Tumor Suppressor

 : :Myosin : :NEA-130 : :NMP22 : :OA-519

 : :Opioid Peptides : :P-glycoprotein

 : :Pancreatic Oncofetal Antigen (POA)

 : :Placental Lactogen

 : :PR92

 : :Proliferative Index, Ki-67

 : :Px



 : :RB Inactivation/Deletion

 : :Ret : :SCCL : :Selectin : :Sialic Acid

 : :Sialyl SSEA-1/SLX

 : :SN10

 : :Somatostatin

 : :TA-90 : :TABA

 : :Tachykinin

 : :TAG : :TPS

 : :Troponin : :Tubulin : :VCAM : :VEGF

 : :Villen and others

- C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- 3. Molecular Diagnostics
- 4. Chromosome Analysis
- a. Chronic Myelogenous Leukemia (CML)
- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
- E. Personal Testing

VIII. COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS,



SUPPLIER SHARES

Australia

Bangladesh

China

Hong Kong

India

Indonesia

Japan

Malaysia

Myanmar

New Zealand

Pakistan

Philippines

Singapore

South Korea

Taiwan

Thailand

Turkey

Vietnam

IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players

and start-up companies with innovative technologies and products, including:

 : :Abbott

 : :Affymetrix

 : :Beckman Coulter/Danaher/Cepheid

 : :Becton Dickinson

 : :bioMerieux

 : :Bio-Rad

 : :DiaSorin

 : :Eiken Chemical

 : :Elitech Group

 : :Enzo Biochem

 : :Fujirebio

 : :Fujifilm Wako

 : :Grifols



 : :Hologic

 : :Leica Biosystems

 : :PerkinElmer

 : :Qiagen

 : :QuidelOrtho

 : :Roche

 : :Siemens Healthineers

 : :Takara Bio

 : :Thermo Fisher and others.



List Of Tables

LIST OF TABLES

Australia Cancer Diagnostic Volume Forecasts by Test Australia Cancer Diagnostics Sales Forecasts by Test Bangladesh Cancer Diagnostic Volume Forecasts by Test Bangladesh Cancer Diagnostics Sales Forecasts by Test China Cancer Diagnostic Volume Forecasts by Test China Cancer Diagnostics Sales Forecasts by Test Hong Kong Cancer Diagnostic Volume Forecasts by Test Hong Kong Cancer Diagnostics Sales Forecasts by Test India Cancer Diagnostic Volume Forecasts by Test India Cancer Diagnostics Sales Forecasts by Test Indonesia Cancer Diagnostic Volume Forecasts by Test Indonesia Cancer Diagnostics Sales Forecasts by Test Japan Executive Summary Table: Total Tumor Marker Test Volume and Sales Forecast by Market Segment Japan, Estimated Cancer Death Rates Per 100,000 Population Japan, Laboratories Performing Tumor Marker Tests by Market Segment Japan, Hospital Laboratories Performing Tumor Marker Tests by Bed Size Japan, Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test Volume Japan, Total Tumor Marker Testing Volume Forecast by Market Segment Japan, All Market Segments Major Tumor Marker Test Volume Forecast Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test

LIST OF TABLES

Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast Japan, Total Tumor Marker Sales



Forecast by Market Segment Japan, All Market Segments Major Tumor Marker Sales Forecast by Test Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Colon-Specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

LIST OF TABLES

Japan, Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Ferritin Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Gastrin Test Volume and



Diagnostics Sales Forecast by Market Segment Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

LIST OF TABLES

Japan, Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment
Japan, PAP Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, PSA Test Volume and Diagnostics Sales
Forecast by Market Segment
Japan, S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market Segment
Japan, Serotonin Test Volume and



Diagnostics Sales Forecast by Market Segment Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment Japan, Total Tumor Marker Sales by Major Suppliers Japan, AFP Testing Market Diagnostics Sales by Major Supplier Japan, CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier

LIST OF TABLES

Japan, CA 125 Testing Market Diagnostics
Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics
Sales by Major Supplier
Japan, PAP Testing Market Diagnostics
Sales by Major Supplier
Japan, PSA Testing Market Diagnostics
Sales by Major Supplier
Malaysia Cancer Diagnostic Volume Forecasts by Test
Malaysia Cancer Diagnostics Sales Forecasts by Test
Myanmar Cancer Diagnostic Volume Forecasts by Test
Myanmar Cancer Diagnostics Sales Forecasts by Test



New Zealand Cancer Diagnostic Volume Forecasts by Test
New Zealand Cancer Diagnostics Sales Forecasts by Test
Pakistan Cancer Diagnostic Volume Forecasts by Test
Pakistan Cancer Diagnostics Sales Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostics Sales Forecasts by Test
South Korea Cancer Diagnostic Volume Forecasts by Test
South Korea Cancer Diagnostics Sales Forecasts by Test
Taiwan Cancer Diagnostic Volume Forecasts by Test
Taiwan Cancer Diagnostics Sales Forecasts by Test
Thailand Cancer Diagnostic Volume Forecasts by Test
Thailand Cancer Diagnostics Sales Forecasts by Test

LIST OF TABLES

Vietnam Cancer Diagnostic Volume Forecasts by Test Vietnam Cancer Diagnostics Sales Forecasts by Test **Tumor Marker Classification** Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or



Marketing Progesterone Receptor Tests
Major Companies Developing or
Marketing Ferritin Tests
Major Companies Developing or
Marketing Gastrin Tests
Major Companies Developing or
Marketing HCG Tests
Major Companies Developing or
Marketing Insulin Tests

LIST OF TABLES

Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications** In Cancer Diagnosis **Oncogenes Potential Applications** In Cancer Diagnosis Major Companies Developing or Marketing Oncogene Tests **Growth Factors Potential Applications** In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications in Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis



I would like to order

Product name: 2023-2027 Asia-Pacific Tumor Markers Testing Market-High-Growth Opportunities for

Cancer Diagnostic Tests and Analyzers-An 18-Country Analysis-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: https://marketpublishers.com/r/221B1A996F56EN.html

Price: US\$ 11,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/221B1A996F56EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$